(Q28272429)

Expert Opinion on Drug Safety

ChEBI release 2020-05-28

1 reference

Andrea Zivi

1

0 references

Linda Cerbone

series ordinal

2

0 references

Federica Recine

series ordinal

3

0 references

Cora N Sternberg

series ordinal

4

0 references

language of work or name

English

0 references

publication date

September 2012

0 references

published in

0 references

volume

11

0 references

issue

5

0 references

page(s)

851-9

0 references

cites work

A quantitative analysis of kinase inhibitor selectivity

1 reference

https://api.crossref.org/works/10.1517/14740338.2012.712108

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.2012.712108

Sorafenib in advanced clear-cell renal-cell carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.2012.712108

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108

Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.712108